$4.49 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 106 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | PEAK BIO INC*w exp 10/26/202 | $0 | – | -362,500 | -100.0% | -0.00% | – | |
| SIEN | Exit | SIENTRA INC | $0 | – | -2,679,950 | -100.0% | -0.01% | – |
| ONCR | Exit | ONCORUS INC | $0 | – | -2,536,186 | -100.0% | -0.01% | – |
| Exit | PEPGEN INC | $0 | – | -60,009 | -100.0% | -0.02% | – | |
| ORTX | Exit | ORCHARD THERAPEUTICS PLCspon ads | $0 | – | -3,161,707 | -100.0% | -0.02% | – |
| GRAY | Exit | GRAYBUG VISION INC | $0 | – | -5,281,713 | -100.0% | -0.06% | – |
| KZR | Exit | KEZAR LIFE SCIENCES INC | $0 | – | -1,430,000 | -100.0% | -0.21% | – |
| PCRX | Exit | PACIRA BIOSCIENCES INC | $0 | – | -292,000 | -100.0% | -0.23% | – |
| APEN | Exit | APOLLO ENDOSURGERY INC | $0 | – | -1,750,000 | -100.0% | -0.36% | – |
| DAWN | Exit | DAY ONE BIOPHARMACEUTICALS I | $0 | – | -964,033 | -100.0% | -0.43% | – |
| IMGN | Exit | IMMUNOGEN INC | $0 | – | -6,358,314 | -100.0% | -0.65% | – |
| Exit | 1LIFE HEALTHCARE INCnote 3.000% 6/1 | $0 | – | -40,599,000 | -100.0% | -0.81% | – | |
| Exit | ALPHATEC HLDGS INCnote 0.750% 8/0 | $0 | – | -48,050,000 | -100.0% | -0.90% | – | |
| PHR | Exit | PHREESIA INC | $0 | – | -1,366,329 | -100.0% | -0.92% | – |
| Exit | NUVASIVE INCnote 1.000% 6/0 | $0 | – | -96,966,000 | -100.0% | -1.97% | – | |
| Exit | SAREPTA THERAPEUTICS INCdbcv 1.500%11/1 | $0 | – | -88,657,000 | -100.0% | -3.42% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.